Together with collaborators, we have reported that the EYA4 gene is hypermethylated in the first intron–exon junction [15], and possibly over-expressed in triple-negative breast cancer patients, which correlates with publicly available TCGA dataset that shows amplification as the most common alteration in breast cancer patients. This evidence concerns the gene EYA4 and breast cancer.